



Use of Negative Pressure Wound Therapy with Automated, Volumetric Instillation for the Treatment of Extremity and Trunk Wounds: Clinical Outcomes and Potential Cost Effectiveness

Gabriel A, Kahn K, Karmy-Jones R. ePlasty 2013 (Nov 3);14:328-338.

Study Purpose

This study:

- compared outcomes of patients whose extremity and trunk wounds were treated with either V.A.C. VERAFLLO™ Therapy or standard V.A.C.® Therapy, and
- developed a hypothetical model to evaluate the cost effectiveness of the two treatments.

Methods

Study Design: Comparative retrospective study

Study Population: Patients (21-80 years of age) with an infected or critically colonized wound treated with either V.A.C. VERAFLLO™ Therapy or standard V.A.C.® Therapy between 1 January 2010 and 31 May 2013

- Patients with pressure ulcers or wounds with infected hardware or implants were excluded.
- 48 patients: V.A.C. VERAFLLO™ Therapy with V.A.C. VERAFLLO™ Dressing with instillation of either saline or Prontosan® (B.Braun Medical Inc., Bethlehem, PA):
 - Set dwell time ranging from 1 to 60 seconds,
 - Followed by V.A.C.® Therapy at -125mmHg for 1 to 2 hours
- 34 patients: V.A.C.® Therapy with V.A.C.® GranuFoam™ Dressing or V.A.C.® GRANUFOAM SILVER™ Dressing at continuous -125mmHg

Methods and Procedures

- All patients were treated by the same investigator using a similar protocol:
 - Wound debridement
 - Systemic antibiotics prior to therapy
 - Dressing changes every 2-3 days
- A hypothetical economic model was developed to estimate average overall costs for V.A.C. VERAFLLO™ Therapy vs V.A.C.® Therapy during the study timeframe
- Data used in the model included:
 - Mean values of actual study results such as hospital length of stay (LOS), number of surgical debridements, length of therapy (LOT), and time to wound closure
 - Cost of a surgical operating room (OR) debridement (\$3,393), based on a published report by Granick and colleagues¹
 - Total therapy cost was calculated from daily cost of therapy of \$194.80 for V.A.C. VERAFLLO™ Therapy and \$106.08 for V.A.C.® Therapy and average LOT
- Categorical data were compared using Fisher's exact test (two-tailed), and continuous variables were compared using Wilcoxon rank sum test (two-sided).

Results

- V.A.C. VERAFLOR™ Therapy patients, compared to V.A.C.® Therapy patients:
 - Required fewer surgical OR debridements (2.0 vs 4.4),
 - Experienced a significantly ($p < 0.0001$) shorter average:
 - » LOS (8.1 vs 27.4 days),
 - » LOT (4.1 vs 20.9 days),
 - » Time to wound closure (4.1 vs 20.9 days)
- Based on the table below, the hypothetical model demonstrated an average reduction of:
 - \$8,143 in OR debridement costs for V.A.C. VERAFLOR™ Therapy versus V.A.C.® Therapy patients (\$6,786 vs \$14,929, respectively), based on average actual frequency of OR debridements (2.0 vs. 4.4, respectively)
 - \$1,418 in therapy cost for the V.A.C. VERAFLOR™ Therapy group (\$799 for V.A.C. VERAFLOR™ Therapy vs \$2,217 for V.A.C.® Therapy), when average length of therapy was multiplied by the daily cost (\$194.80 vs \$106.08, respectively).

	NPWTi-d	NPWT	Difference
Patients	N=48	N=34	
Trips to OR for debridement	2.0	4.4	2.4
Mean cost of an OR debridement¹	\$3,393	\$3,393	-
Total OR debridement cost	\$6,786	\$14,929	\$8,143
Length of NPTWi-d (days)	4.1	-	4.1
Length of NPWT (days)	-	20.9	20.9
Daily cost of therapy^{2*}	\$194.80	\$106.08	(\$88.72)
Total therapy costs	\$799	\$2,217	\$1,418

- As with any retrospective analysis, the authors noted that this study had limitations that included potential selection bias, information bias, and missing data.

Conclusions

- In this comparative retrospective study, the authors reported reductions in hospital LOS, mean time to wound closure, mean surgical debridements, and LOT for V.A.C. VERAFLOR™ Therapy patients compared to V.A.C.® Therapy patients.
- Based on cost savings from fewer OR visits for surgical debridements and reduced length of therapy for V.A.C. VERAFLOR™ Therapy patients, the authors recommended “additional prospective, controlled studies . . . to further assess the comparative cost effectiveness of each treatment.”

Disclosures

Dr. Gabriel is a consultant for KCI, Inc. (San Antonio, TX). The other authors have no financial disclosures.

* NPWTi-d system daily estimated cost—\$194.80 (assumes daily cost of NPWT unit of \$63.25, 0.8 canisters daily at \$42.49 each, 3 medium dressings at \$115 each/average hospital stay, and one cassette at \$55 each; solution cost excluded. NPWT daily estimated cost—\$106.08 (assumes daily cost of NPWT unit of \$63.25, 3 medium dressings per week with mix of silver foam dressings (79%) at \$71.96 each and black foam (21%) at \$50.40 each, 0.3 canisters per day at \$42.49 each).

References:

1. Granick M, Boykin J, Gamelli R, Schultz G, Tenenhaus M. Toward a common language: surgical wound bed preparation and debridement. Wound Repair Regen 2006;14:S1-S10.

NOTE: Healthcare costs are in US dollars and are based on the US market. Actual savings will vary based on country-specific healthcare systems and on individual facility costs, protocol and patients.

NOTE: Specific indications, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a physician and product instructions for use prior to application. This material is intended for healthcare professionals.